ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Lifastuzumab Biosimilar - Anti-SLC34A2 Antibody - BSA and Azide free (A338824)

Recombinant humanized monoclonal antibody to SLC34A2 for use as a research grade Lifastuzumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 7-10 business days.
Name
Lifastuzumab Biosimilar - Anti-SLC34A2 Antibody - BSA and Azide free
Description
Recombinant humanized monoclonal antibody to SLC34A2 for use as a research grade Lifastuzumab biosimilar.
Applications
ELISA, Flow Cytometry, Functional Studies, in vivo Research
Reactivity
Human
Host
Humanized
Clonality
Monoclonal
Isotype
IgG1
Conjugate

Unconjugated

Purity
The purity of this Biosimilar is >95%, as determined by SDS-PAGE.
Product Form
Liquid
Formulation
Supplied in 0.01M Phosphate Buffered Saline, pH 7.4.
Storage
Shipped at 4°C. Upon delivery store at 4°C for short-term use (1-2 weeks) or aliquot and store at -20°C for long-term use (up to 12 months).
Synonyms
Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, NaPi-2b, NaPi3b, Sodium-dependent phosphate transport protein 2B, Sodium-phosphate transport protein 2B, Sodium/phosphate cotransporter 2B, Solute carrier family 34 member 2
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Lifastuzumab Biosimilar - Anti-SLC34A2 Antibody - BSA and Azide free (A338824)? Please let us know so that we can list the citation on this page.

Alternative products to Lifastuzumab Biosimilar - Anti-SLC34A2 Antibody - BSA and Azide free (A338824)

Proteins predicted to interact with SLC34A2

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
92.3% Relevancy Score
91.3% Relevancy Score
90.7% Relevancy Score
88.7% Relevancy Score
84.1% Relevancy Score
79% Relevancy Score
77.9% Relevancy Score
74.7% Relevancy Score
74.5% Relevancy Score